NCT07375901Completed
the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration
The State of the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Patients With Exudative Age-Related Macular Degeneration
Source: ClinicalTrials.gov · Last updated 29 Jan 2026
Brief summary (registry, in English)
To evaluate the status of the blood-aqueous barrier by objectively measuring protein concentration in the aqueous humor using laser flare photometry (LFP) in patients with exudative age-related macular degeneration (AMD) undergoing anti-angiogenic therapy.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 22 Jan 2026
- Start date
- 25 Mar 2021
- Primary completion date
- 15 Apr 2023
- Lead sponsor
- The Filatov Institute of Eye Diseases and Tissue Therapy
- Diseases
- Macular degeneration
- NCT number
- NCT07375901
What you commit to
- Study type: Interventional
- Participants enrolled: 30
- From 25 Mar 2021 to the primary completion date, 15 Apr 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Age in the registry: 47 years to 88 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Filatov Institute of Eye Diseases and Tissue Therapy Coordinator of this site? Confirm its status | Odesa | Ukraine | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.